Advertisement

Nikhil Khushalani, MD

Articles

Looking Ahead: Unmet Needs for the Treatment of BCC

November 9th 2022

Nikhil Khushalani, MD, comments on upcoming treatment advances he looks forward to for patients with BCC.

Treatment Options for Patients with Advanced Basal Cell Carcinoma (BCC)

November 2nd 2022

An expert provides a brief overview of basal cell carcinoma (BCC) and reviews currently available treatment options for patients with BCC.

Future Perspectives in cSCC

November 2nd 2022

Dr Khushalani discusses challenges faced when treating patients with cSCC and shares advice for fellow colleagues who treat patients with cSCC.

Real-World Data of Cemiplimab in Patients with Advanced cSCC

October 26th 2022

Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.

Role of Cemiplimab in the Neoadjuvant Setting for Patients with cSCC

October 26th 2022

Nikhil Khushalani, MD, comments on updated data evaluating the use of cemiplimab in the neoadjuvant setting for patients with cSCC.

Treatment Options for Patients with cSCC in the Neoadjuvant Setting

October 19th 2022

An overview of treatment options for patients for with cSCC, focusing on the neoadjuvant setting.

Overview of Cutaneous Squamous Cell Carcinoma (cSCC)

October 19th 2022

Dr Khushalani defines cutaneous squamous cell carcinoma (cSCC), reviews the risk factors associated, and explains the staging system for patients diagnosed with cSCC.

Dr. Khushalani on the Mechanism of Action of RP1 in Cancer Care

April 22nd 2022

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.

Dr. Khushalani on Goals for the CA045-001 Trial in Melanoma

July 25th 2019

Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Dr. Khushalani on Reasoning for the CA045-001 Trial

July 9th 2019

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Advertisement
Advertisement